 A variety of specialists may be needed.In 2005, the FDA approved the orphan drug galsulfase (Naglazyme) for the treatment of Maroteaux-Lamy syndrome.Galsulfase is an enzyme replacement therapy (ERT) in which the missing ASRB enzyme is replaced with a recombinant version.